Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...
CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident management assignment. Aboard MV Hondius, 12 confirmed and 1 probable Andes ...
FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors. PATINA randomized ...
Interrupted time-series signals showed exacerbations increased before 2015 but dropped sharply after 2015 and continued improving annually thereafter in adults with asthma. The 2015 inflection aligned ...
New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.
From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...
Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...
Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and ...
Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds ...
Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a ...
Tebipenem pivoxil becomes the only FDA-approved oral carbapenem for complicated UTIs/pyelonephritis in adults lacking viable ...
Claims-based ATTR-CM incidence increased >4-fold in Medicare (2010–2021) and ~2.7-fold in commercial insurance (2016–2022), with parallel multi-fold prevalence increases across databases. Higher rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results